Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04452422

Acronym

VT-Covid-19

Enrollment

Registered

2020-06-30

Start date

2020-06-23

Completion date

2020-09-23

Last updated

2021-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Venous Thrombosis

Keywords

non-severe COVID-19, neurovascular diseases, Doppler ultrasound, Deep venous thrombosis, Covid-19, SARS-CoV-2

Brief summary

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Inclusion criteria: * Age\>18 years * COVID-19 confirmed with RT-PCER and/or chest CT-scan * Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke. *

Exclusion criteria

* age\<18 * Other neurovascular diseases

Design outcomes

Primary

Measure	Time frame
Number of cumulated deep venous thrombosis among the hospitalization	Day 7 after admisssion

Countries

France

Outcome results